Literature DB >> 14694103

Nucleocapsid-RNA interactions are essential to structural stability but not to assembly of retroviruses.

Shainn-Wei Wang1, Kristin Noonan, Anna Aldovini.   

Abstract

The process of RNA incorporation into nascent virions is thought to be critical for efficient retroviral particle assembly and production. Here we show that human immunodeficiency virus type 1 mutant particles (which are highly unstable and break down soon after release from the cell) lacking nucleocapsid (NC) core protein-mediated RNA incorporation are produced efficiently and can be recovered at the normal density when viral protease function is abolished. These results demonstrate that RNA binding by Gag is not necessary for retroviral particle assembly. Rather, the RNA interaction with NC is critical for retroviral particle structural stability subsequent to release from the membrane and protease-mediated Gag cleavage. Thus, the NC-RNA interaction, and not simply the presence of RNA, provides the virus with a structural function that is critical for stable retroviral particle architecture.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14694103      PMCID: PMC368744          DOI: 10.1128/jvi.78.2.716-723.2004

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  A model system for nonhomologous recombination between retroviral and cellular RNA.

Authors:  A M Hajjar; M L Linial
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

Review 2.  First glimpses at structure-function relationships of the nucleocapsid protein of retroviruses.

Authors:  J L Darlix; M Lapadat-Tapolsky; H de Rocquigny; B P Roques
Journal:  J Mol Biol       Date:  1995-12-08       Impact factor: 5.469

3.  Specificity and sequence requirements for interactions between various retroviral Gag proteins.

Authors:  E K Franke; H E Yuan; K L Bossolt; S P Goff; J Luban
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

Review 4.  Retroviral RNA packaging: a review.

Authors:  A Rein
Journal:  Arch Virol Suppl       Date:  1994

5.  Human immunodeficiency virus type 1 virion density is not determined by nucleocapsid basic residues.

Authors:  A Cimarelli; J Luban
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

6.  Cleavage of p15 protein in vitro by human immunodeficiency virus type 1 protease is RNA dependent.

Authors:  N Sheng; S Erickson-Viitanen
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

7.  Functional chimeras of the Rous sarcoma virus and human immunodeficiency virus gag proteins.

Authors:  R P Bennett; T D Nelle; J W Wills
Journal:  J Virol       Date:  1993-11       Impact factor: 5.103

8.  Self-assembly in vitro of purified CA-NC proteins from Rous sarcoma virus and human immunodeficiency virus type 1.

Authors:  S Campbell; V M Vogt
Journal:  J Virol       Date:  1995-10       Impact factor: 5.103

9.  Defining the level of human immunodeficiency virus type 1 (HIV-1) protease activity required for HIV-1 particle maturation and infectivity.

Authors:  J R Rosé; L M Babé; C S Craik
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

10.  Specific binding of HIV-1 nucleocapsid protein to PSI RNA in vitro requires N-terminal zinc finger and flanking basic amino acid residues.

Authors:  J Dannull; A Surovoy; G Jung; K Moelling
Journal:  EMBO J       Date:  1994-04-01       Impact factor: 11.598

View more
  26 in total

1.  Role of the C terminus of foamy virus Gag in RNA packaging and Pol expression.

Authors:  Carolyn R Stenbak; Maxine L Linial
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 2.  Properties and functions of the nucleocapsid protein in virus assembly.

Authors:  Delphine Muriaux; Jean-Luc Darlix
Journal:  RNA Biol       Date:  2010-11-01       Impact factor: 4.652

3.  Basic residues in the nucleocapsid domain of Gag are critical for late events of HIV-1 budding.

Authors:  Vincent Dussupt; Paola Sette; Nana F Bello; Melodi P Javid; Kunio Nagashima; Fadila Bouamr
Journal:  J Virol       Date:  2010-12-15       Impact factor: 5.103

4.  Ty3 nucleocapsid controls localization of particle assembly.

Authors:  Liza S Z Larsen; Nadejda Beliakova-Bethell; Virginia Bilanchone; Min Zhang; Anne Lamsa; Rhonda Dasilva; G Wesley Hatfield; Kunio Nagashima; Suzanne Sandmeyer
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

Review 5.  Nucleocapsid protein function in early infection processes.

Authors:  James A Thomas; Robert J Gorelick
Journal:  Virus Res       Date:  2008-02-14       Impact factor: 3.303

6.  Quantitative fluorescence resonance energy transfer microscopy analysis of the human immunodeficiency virus type 1 Gag-Gag interaction: relative contributions of the CA and NC domains and membrane binding.

Authors:  Ian B Hogue; Adam Hoppe; Akira Ono
Journal:  J Virol       Date:  2009-04-29       Impact factor: 5.103

7.  Distinct roles for nucleic acid in in vitro assembly of purified Mason-Pfizer monkey virus CANC proteins.

Authors:  Pavel Ulbrich; Sarka Haubova; Milan V Nermut; Eric Hunter; Michaela Rumlova; Tomas Ruml
Journal:  J Virol       Date:  2006-07       Impact factor: 5.103

8.  Association of human immunodeficiency virus type 1 gag with membrane does not require highly basic sequences in the nucleocapsid: use of a novel Gag multimerization assay.

Authors:  Akira Ono; Abdul A Waheed; Anjali Joshi; Eric O Freed
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

9.  Redundant roles for nucleocapsid and matrix RNA-binding sequences in human immunodeficiency virus type 1 assembly.

Authors:  David E Ott; Lori V Coren; Tracy D Gagliardi
Journal:  J Virol       Date:  2005-11       Impact factor: 5.103

10.  The nucleocapsid region of HIV-1 Gag cooperates with the PTAP and LYPXnL late domains to recruit the cellular machinery necessary for viral budding.

Authors:  Vincent Dussupt; Melodi P Javid; Georges Abou-Jaoudé; Joshua A Jadwin; Jason de La Cruz; Kunio Nagashima; Fadila Bouamr
Journal:  PLoS Pathog       Date:  2009-03-13       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.